Incyte Corporation (INCY) Stock Price & Analysis
Market: NASDAQ • Sector: Healthcare • Industry: Biotechnology
Incyte Corporation (INCY) Profile & Business Summary
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Key Information
| Ticker | INCY |
|---|---|
| Exchange | NASDAQ |
| Official Site | https://www.incyte.com |
Market Trend Overview for INCY
One model, two time views: what the market looks like right now, and where the larger trend is heading over time.
SRE (WhaleQuant Structural Regime Engine) SRE evaluates how price structure evolves across daily and weekly timeframes to define the prevailing market regime. Beyond identifying trends, consolidations, and exhaustion phases, it distinguishes between raw structural strength and deployable participation quality. The model dynamically adjusts for structural context and extension risk, assessing whether conditions are supportive, stretched, fragile, or structurally impaired. Its purpose is not to forecast precise price levels, but to determine whether risk deployment is aligned with underlying market structure.
Longer-Term Market Trend (Mid to Long Term)
Shows the bigger market trend, how strong it is, and where risks may start to build over the next few weeks or months. — Updated as of 2026-07-13 (ET)
As of 2026-07-13, INCY is moving sideways without a clear direction. Over the longer term, the trend remains bullish.
INCY last closed at 114.23. The price is about 0.0 ATR above its recent average price (114.11), and the market is currently in a sideways market without a clear direction. Price at 114.23 is moving between minor support near 97.31 and minor resistance near 115.56. Direction remains unclear. View Support & Resistance from Options
The market is moving sideways, with no clear direction. Both upside and downside risks remain in play.
Trend score: 35 out of 100. Overall alignment is unclear. The market is currently in a sideways market without a clear direction. The longer-term trend is still positive, but short-term signals are not yet confirming it.
A key downside risk boundary is near 100.30. If price falls below this area, the current structure would likely weaken further.
A systematic trend-activation signal was most recently triggered on 2026-06-23, reflecting a technical shift toward positive directional alignment.
[2026-07-13] Price moved quickly and looked strong, but participation was limited.Bearish signal near resistance (0.37 ATR away). Reversal risk is higher. Pattern is less clear, so strength is reduced.
Recent price movement appears increasingly driven by low-effort advances. Such hollow progression often reflects reduced participation and lower reliability of continuation.
Some late-day positioning was observed, but it lacked strong overnight commitment.
The model stays neutral because the setup is not clear enough to justify a directional deployment.
The model does not issue an actionable directional forecast. Predictability is 51%, agreement is 88%, and reversal risk is 12%.
NOTE: This next-day up/down probability forecast module is still being tested for accuracy. Please do not rely on it for investment decisions. The model does not account for black swan events or company-specific fundamental news, and its estimates are based solely on technical conditions, capital flow, and market sentiment. View forecast history
This reading is based on the last 20 trading days of 15-minute price, volume, and VWAP data. Price is modestly above the recent estimated cost basis of 112.76, so the recent structure is still on the firmer side. Price is in the lower half of the main cost band (113.51 to 116.24), so price support and pullback behavior matter more than immediate upside follow-through. The lower down support area sits around 108.38 to 108.61. Recent positioning looks fairly balanced, with 41% in profit and 59% under water. The main cost band is fairly wide relative to recent ATR, so this structure may behave less cleanly than a tighter setup. From a trading point of view, the main question is whether pullbacks remain controlled before price falls back into the lower support zone.